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Abstract Mouse models have been designed for a number of fatty acid oxidation defects. Studies in these mouse models have demonstrated that different pathogenetic mechanisms play a role in the pathophysiology of defects of fatty acid oxidation. Supplementation with L-carnitine does not prevent low tissue carnitine levels and induces acylcarnitine production having potentially toxic effects, as presented in very-long-chain acyl-CoA dehydrogenase (VLCAD)-deficient mice. Energy deficiency appears to be an important mechanism in the development of cardiomyopathy and skeletal myopathy in fatty acid oxidation defects and is also the underlying mechanism of cold intolerance. Hypoglycemia as one major clinical sign in all fatty acid oxidation defects occurs due to a reduced hepatic glucose output and an enhanced peripheral glucose uptake rather than to transcriptional changes that are also observed simultaneously, as presented in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice. There are reports that an impaired fatty acid oxidation also plays a role in intrauterine life. The embryonic loss demonstrated for some enzyme defects in the mouse supports this hypothesis. However, the exact mechanisms are unknown. This observation correlates to maternal hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, as observed in pregnancies carrying a long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)-deficient fetus. Synergistic heterozygosity has been shown in isolated patients and in mouse models to be associated with clinical phenotypes common to fatty acid oxidation disorders. Synergistic mutations may also modulate severity of the clinical phenotype and explain in part clinical heterogeneity of fatty acid oxidation defects. In summary, knowledge about the different pathogenetic mechanisms and the resulting pathophysiology allows the development of specific new therapies. 
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Introduction
Fatty acid oxidation (FAO) defects comprise enzyme deficiencies of long-and medium-chain FAO. A number of mouse models for the different enzyme deficiencies have been designed in order to study the different aspects of disease. Importantly, many of the different mouse models present with similar stress-induced clinical phenotypes as those observed in humans and are excellent models for pathophysiological studies relevant to human patients. The available mouse models of defects in mitochondrial β oxidation of fatty acids are displayed in Table 1 . In humans, long-chain FAO defects present with heterogeneous clinical phenotypes mainly affecting three different organ systems: heart, liver, and skeletal muscles (Wanders et al. 1999) . Whereas some patients present with the full spectrum of disease and a multisystemic disease, others only exhibit hypoglycemia during illness or episodes of rhabdomyolysis due to vigorous exercise. In general, clinical symptoms are mainly induced by catabolism when energy from FAO is needed. Since implementation of newborn screening, a large number of patients remained asymptomatic with preventive measures during the observation period of 5-10 years ). In patients with medium-chain acyl-CoA dehydrogenase (MCAD)-deficiency (MCADD), the common defect of medium-chain FAO, hepatic symptoms only are observed, such as fatty liver and impaired glucose metabolism due to prolonged fasting or catabolism during illness. Factors determining the heterogeneous clinical course of disease and the pathophysiology have been studied in gene-targeted mouse models of long-and medium-chain FAO defects (Schuler and Wood 2002; Spiekerkoetter et al. 2005; van Vlies et al. 2005; Cox et al. 2009; Kurtz et al. 1998 ).
Mouse models and correlation of clinical phenotype in murine and human disease
Mouse models with carnitine palmitoyl-CoA transferase-1a (CPT 1a, liver isoform) (OMIM 600528) and 1b (muscle isoform) (OMIM 601987) deficiencies have been developed and characterized. Both are homozygous lethal in early gestation (Nyman et al. 2005; Ji et al. 2008) . In humans, only CPT 1a deficiency occurs and presents as MCADdeficiency, solely with the hepatic phenotype characterized by hypoketotic hypoglycemia during catabolism. Wood et al. 1989 , Armstrong, et al. 1993 Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) (OMIM 609575) is the commonest of the human long-chain FAO defects. There are two independently developed and characterized VLCAD-deficient mouse models (Cox et al. 2001; Exil et al. 2003) . Both models are characterized by no definite clinical phenotype at rest but present with similar stress-induced phenotypes as those in humans (Spiekerkoetter et al. 2005; Cox et al. 2001) . Therefore, they are good models to study the stress-induced changes occurring in this group of disorders. In the mouse, physical exercise results in impaired running speed and overall impaired running distance (Spiekerkoetter et al. 2005; Spiekerkoetter et al. 2004b ). Fasting and cold exposure result in severe hypoglycemia, hypothermia, and lethargy and is lethal in one third of VLCAD-deficient mice (Spiekerkoetter et al. 2004b ). The full picture of cardiomyopathy is not induced in VLCAD-deficient mice by short-term exercise. However, metabolic changes occur in cardiac tissue.
The β-oxidation cycle contains enzymes with overlapping substrate specificity that oxidize fatty acids with the same chain length. Long-chain acyl-CoA dehydrogenase (LCAD) (OMIM 609576) is highly expressed in mouse tissues, covering a great part of palmitoyl-CoA oxidation, as does VLCAD in humans (Schuler and Wood 2002) . In contrast to the mouse, in human tissues, LCAD is not as highly expressed. For LCAD deficiency, a knock-out mouse model has been designed Cox et al. 2001 ) presenting with nonprogressing cardiac hypertrophy, that is not exercise-or stress induced, in the first weeks of life. However, cardiac function remains normal (Schuler and Wood 2002; Cox et al. 2009 ). The LCADdeficient mouse is a good model in which to study cardiac morphological changes in long-chain FAO disorders and closely mimics cardiac changes in human VLCADD.
For MCAD deficiency (MCADD) (OMIM 607008), an MCAD-deficient mouse model has also been designed (Tolwani et al. 2005) , presenting with fatty liver and profound cold intolerance at 4ºC with prior fasting. There was significant neonatal mortality of MCAD-deficient pups (Tolwani et al. 2005) , demonstrating similarities to patterns of clinical episodes and mortality in MCADD patients prior to the newborn screening era. As the MCADdeficient mouse reproduces important aspects of human MCADD and mainly presents with hepatic clinical disease, it is a valuable model to study solely hepatic pathogenetic mechanisms.
The mouse model of trifunctional protein (TFP) deficiency (TFPD) (HADHB OMIM 143450, HADHA OMIM 600890) with deficiency of the TFP α-subunit, is lethal, as is severe TFPD in humans (Ibdah et al. 2001; Spiekerkoetter et al. 2004a) . In humans, in addition, a milder phenotype of TFPD exists that presents with myopathy and irreversible peripheral neuropathy with later onset.
Pathophysiology
Importantly, most symptoms occurring in humans with longchain FAO defects are completely reversible with therapeutic measures and sufficient energy supply ). Cardiomyopathy and pericardial effusion completely reverse within a few weeks (Brown-Harrison et al. 1996; Spiekerkoetter et al. 2003) . Skeletal myopathy can be prevented with medium-chain triglyceride (MCT) supplementation prior to exercise (Gillingham et al. 2006; Spiekerkoetter 2007) . Some long-term complications occurring in disorders of mitochondrial TFPD, including human long-chain 3-hydroxacyl-CoA dehydrogenase (LCHAD) deficiency (OMIM 600890) such as peripheral neuropathy and retinopathy, however, are not reversible with treatment, suggesting other pathogenetic mechanisms than energy deficiency. Different mechanisms underlying the pathophysiology have been demonstrated in the respective mouse models (Schuler and Wood 2002; Spiekerkoetter et al. 2005; Cox et al. 2009 ). This paper discusses these mechanisms and related pathophysiology, along with available evidence, in the development of different clinical phenotypes. The mechanisms addressed here are:
-Carnitine depletion -Accumulation of toxic metabolites -Energy deficiency -Disturbed hepatic carbohydrate management -Impairment of intrauterine fatty acid oxidation -Synergistic heterozygosity Carnitine depletion VLCAD-deficient mice, as humans with VLCADD, present with lower concentrations of free carnitine in blood than healthy controls (Spiekerkoetter et al. 2004b) . Whereas, 1-h exercise training on the treadmill does not result in any changes compared with baseline free carnitine concentrations, after fasting and cold exposure for 8 h, blood-free carnitine concentrations are significantly lower in knock-out and wild-type mice compared with in the resting conditions (Spiekerkoetter et al. 2004b) . Intermittently low free carnitine in blood has led to the hypothesis that carnitine depletion develops and is important in disease pathogenesis. This situation has been characterized as secondary carnitine deficiency in FAO defects. With accumulating acyl-CoA esters in defects of FAO, free carnitine is needed for their conversion into acylcarnitines and their shuttle out of the mitochondria in order to provide sufficient free CoA for other metabolic reactions. The hypothesis of depleted free CoA and depleted tissue carnitine has resulted in therapeutic L-carnitine supplementation in defects of FAO (Winter 2003) .
Recent studies in the mouse model of VLCADD, however, have shown for the first time that blood and tissue free carnitine concentrations do not correlate (Spiekerkoetter et al. 2005) . In VLCAD knock-out mice free carnitine concentrations significantly decreased in skeletal muscle after 1 h of exercise, with this effect not being visible in blood (Spiekerkoetter et al. 2005) . At the same time, free carnitine concentrations in liver significantly increased, strongly suggesting induced endogenous carnitine biosynthesis. Skeletal muscle lacks the final enzyme of the carnitine biosynthesis pathway and therefore is not feasible to replenish low carnitine concentrations itself (Vaz and Wanders 2002) . Importantly, 24 h after 1 h of exercise training, low free carnitine in skeletal muscle is again replenished and reaches initial baseline concentrations (Primassin et al. 2008 ). The same is observed in the heart from VLCAD-deficient mice. In addition, further studies with L-carnitine supplementation (200 mg/kg) demonstrate that exercise-induced reduction of free carnitine in skeletal muscle cannot be prevented with L-carnitine supplementation. It is again active endogenous carnitine biosynthesis that replenishes low carnitine tissue concentrations, even with concurrent L-carnitine supplementation.
In contrast to reduced free carnitine in muscle after exercise, fasting and cold exposure do not result in reduced carnitine concentrations in tissues. However, carnitine biosynthesis is also induced in the liver. The fasting stress mainly affects the liver. Therefore, a reduced free carnitine would be most likely expected in the liver. The low free carnitine concentrations in blood after fasting and cold exposure are misleading, indicating carnitine deficiency. However, they do not correlate with any carnitine tissue concentration measured simultaneously (Spiekerkoetter et al. 2005) .
In conclusion, studies in the VLCAD-deficient mouse model suggest that endogenous carnitine biosynthesis plays the most important role in carnitine homeostasis and replenishes low tissue carnitine concentrations. In contrast, despite continuous oral carnitine supplementation that is constantly high enough, carnitine tissue levels cannot be provided as presented for skeletal muscle after physical exercise. In addition, blood free carnitine concentrations do not reflect the tissue levels and are insufficient markers for carnitine biosynthesis. These data suggest: (1) no permanent carnitine deficiency in tissues is responsible for the development of clinical symptoms in FAO defects, and (2) a lack of effectiveness of L-carnitine supplementation to prevent low tissue carnitine concentrations and to replenish them.
Accumulation of toxic metabolites
In humans with long-chain FAO defects, long-chain acylcarnitines accumulate during metabolic derangement. This observation is also used for diagnostic purposes, including newborn screening. However, it is also known that acylcarnitines can be completely normal during anabolic conditions (Schymik et al. 2006 ). The mouse model of VLCADD, especially after fasting and cold exposure, presents with elevated plasma long-chain acylcarnitines; however, there is also a significant rise in longchain acylcarnitines in wild-type mice under these conditions (Spiekerkoetter et al. 2004b ). These effects are well confirmed by measurements of liver acylcarnitines (Spiekerkoetter et al. 2005) . In contrast, physical exercise of 1 h in mice does not result in an increase in acylcarnitines in blood compared with resting conditions (Spiekerkoetter et al. 2004b ). However, concurrent acylcarnitine measurements in skeletal muscle after physical exercise reveal a significant increase in acylcarnitine production, suggesting no correlation between muscle and blood concentrations. Importantly, after a regeneration period of 24 h, these long-chain acylcarnitines decrease again to baseline levels (Primassin et al. 2008 ). This has not only been observed in skeletal muscle but also in cardiac muscle.
In VLCAD-deficient mice, carnitine supplementation significantly induced long-chain acylcarnitine production in skeletal muscle. This rise in tissue long-chain acylcarnitines was even higher when mice were additionally subjected to physical exercise. These results are threatening, as toxic and arrhythmogenic effects are attributed to long-chain acylcarnitines (Bonnet et al. 1999) . It is still debated whether unphysiologically high concentrations of long-chain acyl-CoA esters are also toxic. Human hepatocellular carcinoma (Hep G2) cells were incubated with palmitoyl carnitine and palmitoyl-CoA at different concentrations, and cell viability was affected by palmitoyl carnitine at much lower concentrations compared with palmitoyl-CoA, suggesting a higher toxic potential of long-chain acylcarnitines (Primassin et al. 2008 ). Acylcarnitine accumulation and acyl-CoA accumulation directly correlate and are in balance, as demonstrated by ter Veld et al. (ter Veld et al. 2009 ). However, acylcarnitines are in general measurable in higher concentrations than acyl-CoA ester (ter Veld et al. 2009 ). We speculate that with carnitine supplementation the balance of both metabolites would shift to increased production of acylcarnitines.
In summary, in the mouse model of VLCADD, there is tissue-specific acylcarnitine production according to the stressor applied with highly elevated acylcarnitine production in skeletal muscle after exercise. Threatening is the fact that L-carnitine supplementation significantly induces acylcarnitine production, especially after exercise (without replenishing free carnitine in skeletal muscle). In vitro studies suggest that long-chain acylcarnitines are more toxic than the corresponding long-chain acyl-CoA ester, however, this has to be further studied in vivo. Toxic effects of accumulating metabolites seem to play an important role in disease pathogenesis since the tissuespecific accumulation due to different stressors directly correlates with the clinical symptoms namely skeletal myopathy after exercise and hepatopathy after fasting.
Energy deficiency
Energy deficiency due to impaired long-chain FAO especially affects high-energetic organs such as the heart or skeletal muscle. Disease episodes occur in situations of increased energy demand such as exercise or illnesses when energy from carbohydrates has been used up and FAO is activated to provide energy from fat. Exil and coworkers have shown in different tissues from VLCAD-deficient mice that mitochondrial proliferation appears to be compensating for impaired β-oxidation and energy deficiency (Exil et al. 2003) . In fact, under resting conditions VLCAD-deficient mice, as occurs in human patients, do not present with skeletal myopathy. The same occurs to the heart at rest with no echocardiographic signs of cardiomyopathy, however the same group demonstrated abnormal mitochondrial bioenergetics and heart rate dysfunction (Exil et al. 2006) . Additionally, cardiac function of VLCAD-deficient mice assessed by MRI revealed a significantly reduced stroke volume as compared to wild-type mice suggesting impaired cardiac function without changes in cardiac morphology (ter Veld et al. 2008) . Longer-term exercise over a period of 2 weeks, however, also induced morphological cardiac changes (ter Veld et al. 2008 ). There are reports from clinical practice in different long-chain FAO defects demonstrating prevention of muscle weakness and pain as well as episodes of rhabdomyolysis with MCT supplementation immediately prior to exercise, providing sufficient energy during increased energy demand (Spiekerkoetter 2007; Gillingham et al. 2006) . The effects have also been studied in the mouse model of VLCADD and could be directly confirmed with much less accumulation of long-chain acylcarnitines in skeletal muscle after exercise after an MCT bolus prior to exercise, suggesting sufficient energy production from MCT fat.
Cold intolerance
There are at least three crucial components of nonshivering thermogenesis as demonstrated in gene-targeted mouse models. These include an intact β-adrenergic signaling system, a mitochondrial FAO pathway, and expression of mitochondrial uncoupling protein-1 (UCP-1). The first example of cold intolerance demonstrated in mouse models of FAO deficiencies was described by Guerra et al. (1998) . Fatal cold intolerance in the well-characterized short-chain acyl-CoA dehydrogenase (SCAD)-deficient mouse model (Wood et al. 1989; Amendt et al. 1992; Hinsdale et al. 1993; Armstrong et al. 1993 ) and in the LCAD-deficient mouse model , Cox et al., 2001 ) was reported to occur due to the inability to adequately accomplish nonshivering thermogenesis when placed in a cold laboratory room at 4°C (Guerra, et al. 1998 ). Previously, it had been shown that mice deficient in UCP-1 were also cold intolerant (Enerback et al. 1997) . Although they had an intact adrenergic system and a complete FAO pathway, they were unable to uncouple the generated energy for adenosine triphosphate (ATP) production and turn it into heat. In contrast, mice with FAO deficiencies were unable to generate the energy required to uncouple and produce heat. Additionally, in the case of the SCAD-deficient mice, significantly lower expression of UCP-1 was demonstrated; whereas, UCP-2 expression was significantly higher (Guerra et al. 1998 ). Whereas FAO is crucial for nonshivering thermogenesis, acyl-CoA dehydrogenase gene expression in brown fat is not influenced by cold exposure, and FAO genes are not regulated by peroxisomal proliferator activated receptor alpha (PPAR-α) as they are in liver (Goetzman et al. 2005 ).
Disturbed hepatic carbohydrate management
In contrast to long-chain FAO defects, MCADD generally presents with a hepatic phenotype in human patients. Cardiomyopathy and myopathy do not occur. However, the hepatic disease signs such as hypoglycemia, hepatic dysfunction, and hepatomegaly due to steatosis completely resemble those found in human VLCADD or other long-chain FAO defects. Also in MCADD, symptoms are mainly induced by catabolism, e.g., during prolonged fasting or illnesses. Therefore, in mice with MCADD, hepatic carbohydrate management has been studied during fasting (Tolwani et al. 2005) and during a lipopolysaccharide (LPS)-induced acutephase response (APR) (Herrema et al. 2008) . During the APR, both, MCAD-deficient and wild-type mice became hypoglycemic. However, after a 24-h fasting period only, no hypoglycemia was observed. Flux studies have shown that the de novo synthesis of glucose-6-phosphate (G6P) was not impaired on fasting but was significantly decreased (−20%) during the APR. In addition, newly formed G6P was preferentially directed toward glycogen under both conditions. Interestingly, the expression of different transcription factors, such as hepatic peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), peroxisome proliferator-activated receptor alpha (PPAR-α), and pyruvate dehydrogenase kinase 4 (PDK4), which all regulate fatty acid and glucose oxidation, suggest altered control of hepatic glucose metabolism during fasting and during APR (Herrema et al. 2008) . PPAR-α is known to be a major regulator of FAO, regulating the expression of FAO enzymes and fatty acid transporters. PGC-1α is a major energy-regulating transcriptional coactivator upstream of PPAR-α and has wide influence on most energy-producing pathways depending on its binding partners, such as PPAR-α. PDK4 is the most important kinase that phosphorylates and therefore inhibits the pyruvate dehydrogenase complex in times of reduced glucose utilization.
In summary, transcriptional changes of factors regulating fatty acid and glucose oxidation occur in MCAD-deficient mice after different stressors and suggest an altered control of hepatic glucose metabolism. However, hepatic glucose output is reduced in MCAD-deficient mice only during an APR. Overall, enhanced peripheral glucose uptake due to increased glucose consumption during energy deficiency occurs to be the major pathogenetic mechanism responsible for the development of hypoglycemia (Herrema et al. 2008 ).
Impairment of intrauterine fatty acid oxidation
It is proposed that mitochondrial FAO does not play an important role in intrauterine life, and it has been demonstrated that FAO genes are significantly upregulated after birth (Oey et al. 2006) . However, there are reports in humans of severe intrauterine cardiomyopathy that is lethal after birth . One reason for fetal disease and maternal HELLP syndrome has been proposed as deficient FAO in the placenta (Rakheja et al. 2002) . There is also a significant embryonic loss in LCAD- ), CPT-1a- (Nyman et al. 2005) , and CPT-1b- (Ji et al. 2008 ) deficient mice. LCAD deficiency produces significant gestational losses of both homozygous and heterozygous mutant offspring . However, around 50-60% of mice with LCAD deficiency survive to birth and live into adulthood. Homozygous LCAD-deficient embryos appear to die around day 4-5 of gestation, when the embryo is transforming from a morula into a blastocyst (Berger and Wood 2004) , a process that requires considerable energy. Furthermore, it was not possible to rescue LCADdeficient embryos in culture with medium-or short-chain fatty acid supplementation (Berger and Wood 2004) . In contrast to the reduced gestational survival of homozygous LCAD mice, there has never been a live-born homozygous CPT-1a (Nyman et al. 2005) or CPT-1b mouse (Ji et al. 2008) . These two enzyme deficiencies appear to be much more severe in homozygous mice and apparently kill the embryo sometime before day 10 of gestation (Nyman et al. 2005; Ji et al. 2008) . In conclusion, these data suggest that intrauterine mitochondrial FAO is of relevance and that energy production from glucose oxidation is not always sufficient in utero. However, the exact mechanisms for the embryonic loss remain unsolved, e.g., whether energy deficiency is the main problem or whether additional toxic effects of accumulating metabolites also play a role.
Synergistic heterozygosity
Vockley and coworkers (Vockley et al. 2000) hypothesized that patients with typical clinical/pathologic features of an inborn error of FAO, yet no clear enzyme deficiency or metabolite pattern indicating a specific homozygous deficiency, could be double heterozygous for two different enzyme deficiencies resulting in a clinical disease episode. They reported tantalizing data from a few patients with clearly two partial deficiencies and clinical disease symptoms. They called this genetic hypothesis "synergistic heterozygosity." That is, individuals with two different heterozygous enzyme deficiencies in the same metabolic pathway (mitochondrial FAO) will be at risk for acute metabolic disease. This might explain some patients with a disease phenotype without an unequivocal diagnostic enzyme deficiency/metabolite pattern.
This concept was further investigated in some mouse models of FAO deficiencies. As reported previously Wood 2002, Schuler et al. 2005) , synergistic heterozygosity was demonstrated in various heterozygous combinations of VLCAD+/−//LCAD+/−//SCAD+/−mice. In general, double heterozygous combinations of VLCAD+/−// LCAD+/−, or LCAD+/−//SCAD+/− and the triple combination VLCAD+/−//LCAD+/−/SCAD+/− all produced fatal cold intolerance in ∼33% of mice. In contrast, wild-type and single heterozygous control groups showed 100% normal cold tolerance. Furthermore, the accompanying biochemical characteristics such as acylcarnitine and fatty acid profiles appeared modestly abnormal. Overall, as far as serum acylcarnitine profiles were concerned, LCAD+/−//SCAD+/− and VLCAD+/−//LCAD+/− mice had patterns similar to both LCAD−/− and VLCAD−/− mice. VLCAD+/−//LCAD+/−// SCAD+/− mice had a pattern most similar to wild-type mice. There was no indicator, such as butyrylcarnitine, indicating SCAD+/− deficiency (Wood et al. 1989) . Regarding free fatty acid profiles in serum, VLCAD+/−//LCAD+/− mice had patterns similar to VLCAD−/− (i.e., no C 14:1 ), whereas LCAD+/−//SCAD+/− and VLCAD+/−//LCAD+/−//SCAD+/− mice had patterns similar to wild-type mice. Thus, double/triple heterozygosity in the mouse model can produce acute disease under metabolic challenge with ambiguous biochemical profiles. Furthermore, the disease phenotype is not as severe as that found in homozygous enzyme deficiencies involving the same enzymes.
These initial studies require further investigations with special respect to genotype/phenotype relationships. Critical areas of investigation include whether and how changes in metabolite pools affect the normal rate-limiting steps from being properly regulated ones to ones that occur by default because of the 50% functional deficiency without the proper normal regulation.
In summary, synergistic heterozygosity may explain why some patients with a disease phenotype do not present with an unequivocal diagnostic enzyme deficiency/metabolite pattern. This mechanism may also be of importance in severe clinical manifestations of otherwise milder deficiencies such as VLCADD due to an additional mutation in one of the other FAO enzymes.
Conclusions
As reviewed here, the mouse models representing a range of enzyme deficiencies in the FAO pathway have been instrumental in further understanding the pathophysiology of these disorders in humans. These studies point the way to new therapies or preventive measures for this group of potentially fatal disorders affecting children.
